LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.2 -1.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.16

Max

1.22

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Aktsiakasum	-0.04
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+228.1% upside

Turustatistika
By TradingEconomics
Turukapital	-51M 443M
Eelmine avamishind	2.84
Eelmine sulgemishind	1.2

Uudiste sentiment

By Acuity

40%

60%

127 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. dets 2025, 15:21 UTC

Tulu

Correction to Home Depot Outlook Headline on Dec. 9

23. dets 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. dets 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 21:21 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Hold Deposit in Escrow

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. dets 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. dets 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. dets 2025, 19:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. dets 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. dets 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. dets 2025, 17:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. dets 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. dets 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. dets 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank: Closing Expected Around Mid-January

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. dets 2025, 16:02 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. dets 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Receives Green Light for Acquisition in Poland

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica Doesn't Set Out Financial Details of Divestment

23. dets 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Deal Will Allow Focus on Core Markets

23. dets 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. dets 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

228.1% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD 228.1%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

127 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.